Evidence map›Paper›PMID 20007707›Full record

ArticleThe Journal of biological chemistry2010

The protein-protein interface evolution acts in a similar way to antibody affinity maturation.

Bohua Li, Lei Zhao, Chong Wang, Huaizu Guo, Lan Wu, Xunming Zhang, Weizhu Qian, Hao Wang, Yajun Guo

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. IsAb: a computational protocol for antibody design.Briefings in bioinformatics · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bohua LiFrom the International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433; the National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai 201203, and.
Lei ZhaoFrom the International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433.
Chong Wangthe School of Medicine and School of Pharmacy, The Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, 227 South Chongqing Road, Shanghai 200025, China.
Huaizu Guothe School of Medicine and School of Pharmacy, The Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, 227 South Chongqing Road, Shanghai 200025, China.
Lan WuFrom the International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433.
Xunming ZhangFrom the International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433.
Weizhu QianFrom the International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433; the National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai 201203, and.
Hao WangFrom the International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433; the National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai 201203, and.
Yajun GuoFrom the International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433; the National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai 201203, and; the School of Medicine and School of Pharmacy, The Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, 227 South Chongqing Road, Shanghai 200025, China. Electronic address: yjguo@smmu.edu.cn.
Second Military Medical University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the evolutionary mechanism that acts at the interfaces of protein-protein complexes is a fundamental issue with high interest for delineating the macromolecular complexes and networks responsible for regulation and complexity in biological systems. To investigate whether the evolution of protein-protein interface acts in a similar way as antibody affinity maturation, we incorporated evolutionary information derived from antibody affinity maturation with common simulation techniques to evaluate prediction success rates of the computational method in affinity improvement in four different systems: antibody-receptor, antibody-peptide, receptor-membrane ligand, and receptor-soluble ligand. It was interesting to find that the same evolutionary information could improve the prediction success rates in all the four protein-protein complexes with an exceptional high accuracy (>57%). One of the most striking findings in our present study is that not only in the antibody-combining site but in other protein-protein interfaces almost all of the affinity-enhancing mutations are located at the germline hotspot sequences (RGYW or WA), indicating that DNA hot spot mechanisms may be widely used in the evolution of protein-protein interfaces. Our data suggest that the evolution of distinct protein-protein interfaces may use the same basic strategy under selection pressure to maintain interactions. Additionally, our data indicate that classical simulation techniques incorporating the evolutionary information derived from in vivo antibody affinity maturation can be utilized as a powerful tool to improve the binding affinity of protein-protein complex with a high accuracy.

Indexed as

Evolution, MolecularAmino Acid SequenceAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntibody AffinityAntigens, CDBase SequenceBinding SitesComputer SimulationCrystallography, X-RayCTLA-4 AntigenInterleukin-2 Receptor alpha SubunitModels, MolecularMolecular Sequence DataMutationProtein BindingAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CDCTLA-4 AntigenInterleukin-2 Receptor alpha SubunitProteinsRituximab

Identifiers

PMID20007707
PMCPMC2823529
OpenAlexW1996526198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.